Key facts
- This page summarizes Laurie Stelzer's Form 4 filing for PMV Pharmaceuticals, Inc. (PMVP).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 05 Jun 2026, 16:32.
Laurie Stelzer - 04 Jun 2026 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)
- Reporting relationship
- Director
- Issuer ticker
- PMVP
- Reported as of
- 04 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jun 2026, 16:32:51 UTC
- Prior SEC filing
- 29 May 2026
- Next SEC filing
- 18 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Ticktin, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Laurie Stelzer filed Form 4 for PMV Pharmaceuticals, Inc. (PMVP) on 05 Jun 2026.
Change
- Previous filing in this sequence was filed on 29 May 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001644348
Primary reporting owner
Stelzer Laurie
- Relationship
- Director
- Address
- C/O PMV PHARMACEUTICALS, INC., 400 ALEXANDER PARK DRIVE, SUITE 301, PRINCETON
- Signature
- /s/ Robert Ticktin, by power of attorney
- Signature date
- 05 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PMVP
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +42,000
- Change %
- Price
- $0.000000*
- Shares after
- 42,000
- Date
- 04 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 42,000
- Exercise price
- $1.19
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.